UNSPSC 51452801: Ivermectin

This classification denotes an antiparasitic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8883YP2R6D. European Medicines Agency schedules Ivermectin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12089MIG. Ivermectin generally arises in the molecular formula C48H74O14.

The term IVERMECTIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) IVERMECTIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ivermectin under HS 29419000 and SITC 54139. As of Q4 2014, IVERMECTIN remains the US FDA Preferred Term for this commodity. Ivermectin bears US NLM identifiers UMLS ID C0022322 and NCI Concept Code C61796.

UNSPSC 51452801 Ivermectin is a Commodity code that state and local governments are not actively procuring under this specific classification in recent solicitations. The four recent opportunities tagged to this code—naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative RFI (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue (City of Tampa), and generic multi-source pharmaceuticals through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance)—represent naloxone, emergency medical supplies, and broad-based pharmaceutical procurement, none of which align with ivermectin as an antiparasitic agent. The mismatch suggests either that state and local procurement offices are tagging unrelated health and pharmaceutical acquisitions to this code, or that ivermectin procurement activity does not currently surface in publicly posted state and local notices.

The issuing bodies in the recent opportunities span state health agencies (Texas HHS), county health departments (Seminole County), municipal fire departments (Tampa), and multistate cooperative purchasing consortia (MMCAP), indicating fragmented demand across health, emergency response, and pharmaceutical benefit programs. Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon (through MMCAP participation), though the code's actual ivermectin procurement—if it exists in state and local markets—does not appear in these recent notices. Prospective vendors should investigate whether ivermectin acquisition falls under higher-tier pharmaceutical or health-supply codes, or whether state and local demand for this product is minimal or routed through federal supply chains and standalone pharmaceutical procurement rather than through general state and local competitive bidding.